medigraphic.com
SPANISH

Enfermedades Infecciosas y Microbiología

  • Contents
  • View Archive
  • Information
    • General Information        
    • Directory
  • Publish
    • Instructions for authors        
  • medigraphic.com
    • Home
    • Journals index            
    • Register / Login
  • Mi perfil

2025, Number 2

<< Back Next >>

Enf Infec Microbiol 2025; 45 (2)

Acquired perforating dermatosis, a challenge in the diagnosis of dermatological diseases in patients with chronic kidney disease

Mendoza-Gómez JM, Hernández-Ricárdez EI
Full text How to cite this article

Language: Spanish
References: 8
Page: 105-107
PDF size: 266.24 Kb.


Key words:

acquired perforating dermatitis, diabetes mellitus, chronic renal failure, peritoneal dialysis, hemodialysis.

ABSTRACT

Perforating disorders are a group of diseases characterized by transepidermal extrusion of dermal material. The etiopathogenesis is unknown; however, the acquired form is usually associated with systemic diseases such as renal failure and diabetes mellitus, among others. Pruritus is the cardinal symptom of this pathology, and clinically it presents papulo-nodules centered by keratotic crusts. Regarding treatment, acquired perforating dermatosis (apd) is difficult to control, with a tendency to become chronic.
The case of a 44-year-old female patient with a history of type 2 diabetes mellitus, arterial hypertension and renal failure, with generalized pruritus of several months’ duration and hyperchromic, crateriform lesions and abscesses is presented.


REFERENCES

  1. Yu, A.S.L., Chertow, G.M., Luyckx, V., Marsden, P.A.,Skorecki, K. y Taal, M.W. (eds.), Brenner y Rector. El riñón,Barcelona, Elsevier, 2021.

  2. Arias, M., La Forgia, M., Buonsante, M.E., Portaluppi,M., Kien, M.C. y Pellerano, G., “Dermatosis perforanteadquirida en pacientes con insuficiencia renal crónica.Comunicación de tres casos y revisión de la literatura”,Dermatol Argent, 2007, 13: 184-189.

  3. Griffiths, C.E., Dubertret, L., Ellis, C.N., Finlay, A.Y., Finzi,A.F., Ho, V.C. et al., “Ciclosporin in psoriasis clinicalpractice: an international consensus statement”, Br JDermatol, 2004, 150 (Suppl 67): 11-23.

  4. Cuchía, H.J., Salamanca, A.P. y Peñaranda, E., “Dermatosisperforante adquirida: tratamiento con alopurinol”,Rev Asoc Col Dermatol, 2009, 17: 134-137.

  5. González-Lara, A., Gómez-Bernala S., Vázquez-López, F.y Vivanco-Allende, B., “Dermatosis perforante adquirida:presentación de 8 casos”, Actas Dermosifiliogr,2014, 105 (6): e39-e43.

  6. Viejo-Boyano, I., López-Romero, L.C., Martínez-i-Cózar,V., Soldevila-Orient, A. y Hernández-Jaras, J., “Acquiredperforating dermatosis in patients on peritoneal dialysis:a report of 3 cases”, ame Case Rep, 2023, 7: 46.

  7. Veliz, A., Cheli, S., Territoriale, O., Burguesser, V., Veliz,A., Cheli, S. et al., “Dermatosis perforante adquirida (enfermedadde Kyrle)”, Revista Argentina de Dermatología[Internet], 2021, 102 (4): 31-40.

  8. “Signos cutáneos de insuficiencia renal”. En Saavedra,A.P., Roh, E.K. y Mikailov, A. (eds.), Fitzpatrick. Atlas dedermatología clínica, 9ª ed., McGraw Hill Educación,2023. Consultado el 31 de mayo de 2024. Disponible en:https://accessmedicina.mhmedical.com/content.aspx?-bookid=3362§ionid=280107461.




2020     |     www.medigraphic.com

Mi perfil

C?MO CITAR (Vancouver)

Enf Infec Microbiol. 2025;45